VIVOS news

The company approved the creation of Series C Convertible Preferred Stock with a stated value of $12 million, signaling a potential capital raising event and signaling investor confidence.

Vivos Therapeutics agreed to acquire approximately 11% equity and a 50% interest in new IP from SOD Sciences, and will issue $12M in convertible preferred stock as consideration.

VIVOS Inc removed its Series C Convertible Preferred Stock designation after all shares were converted. This simplifies the capital structure.

Vivos Inc filed an 8-K creating Series D Convertible Preferred Stock. This preferred stock offers voting rights equivalent to 50 votes per conversion share.

Vivos Therapeutics and CFO Bradford Amman signed a separation agreement on July 31, 2026, resulting in his resignation from all executive and board roles while retaining an advisory position to support a transition.